Woman with Atopic Dermatitis symptoms.

ONCE-DAILY ORAL JAK inhibitor indicated for the treatment of adults and pediatric patients 12+ years of age with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1


#1 prescribed oral JAK Inhibitor in AD.

*As of 7/2022. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP).

*As of 7/2022. Source: Integrated Symphony Health (PatientSource) and IQVIA (NSP).


EASI 75 measured at Week 16, and rates seen as early as Week 2

Reduced worst pruritus NRS ≥4 measured at Week 16, rates observed within 2 days after first dose


Co-primary endpoints EASI 75 and vIGA 0/1 controlled at Week 16

Response rates observed up to 52 weeks


90% skin improvement (EASI 90) measured at Week 16


Clinical trial experience in >10,900 patients since 2012 across 6 approved indications

Safety rates up to 3 years in adults and pediatric patients 12+ years in AD8,9

Commitment to exceptional access and patient support with

RINVOQ Complete logo

RINVOQ Complete offers patients the resources and support they need to start
and stay on track with RINVOQ as prescribed.

for eligible patients who experience initial coverage delays or denials.

Handshake icon.

Connects patients with Nurse Ambassadors* and Insurance Specialists

Messaging icon.

Committed to exceptional national commercial coverage, providing access to the medicine patients are prescribed

Payment icon.

Eligible, commercially insured patients can save on their RINVOQ prescription and required lab tests


RINVOQ is an oral, once-daily therapy.1

For adults <65 years and pediatric patients 12+ years weighing at least 40 kg (88 lb), initiate treatment with RINVOQ 15 mg once-daily in pediatric patients (≥12 years, ≥40 kg) and adults <65 years of age. If an adequate response is not achieved, consider increasing the dosage to 30 mg once-daily. Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose needed to maintain response. For patients ≥65 years, patients receiving strong CYP3A4 inhibitors, and patients with severe renal impairment, the recommended dose of RINVOQ is 15 mg once-daily. Coadministration of RINVOQ with strong CYP3A4 inducers is not recommended.1

RINVOQ® (upadacitinib) packaging. RINVOQ® (upadacitinib) packaging. RINVOQ® (upadacitinib) packaging.
Poll results icon.

Want to learn about rapid skin clearance patients can see? In clinical studies
of RINVOQ, many patients achieved EASI 75 and vIGA 0/1 at Week 16.1

Itching to see more? See what patients experienced with RINVOQ in clinical trials.

Are your patients seeking treatment for the rash of atopic dermatitis?

Is itch a primary concern?

Safety is important to you. Want to know more about the safety profile of RINVOQ?

Want to know more about monitoring guidelines for RINVOQ?

RINVOQ Complete can help patients get the support they need to start
and stay on track with their prescribed treatment.

Familiar with Complete? RINVOQ Complete offers the same exceptional
AbbVie support you know and trust.

Connect with a Rep or sign up for more information